Clinical Trials on Locally Advanced Unresectable Gastric Adenocarcinoma in China

Total 792 results

Sichuan Baili Pharmaceutical Co., Ltd.
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Not yet recruiting

A Study of BL-M07D1+PD-1 Monoclonal Antibody and BL-M07D1+PD-1 Monoclonal Antibody+Capecitabine in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma

HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma

China
Sichuan Baili Pharmaceutical Co., Ltd.
SystImmune Inc.; Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Recruiting

A Study of BL-M07D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Low Expression Breast Cancer and Other Solid Tumors

Breast Cancer | Locally Advanced or Metastatic Solid Tumor

China
Peking University Cancer Hospital & Institute

Recruiting

Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC

Unresectable Hepatocellular Carcinoma

China
Wuhan YZY Biopharma Co., Ltd.

Active, not recruiting

A Trial of Y101D in Combination With Gemcitabine and Albumin Paclitaxel in Patients With Advanced Pancreatic Cancer

Advanced Pancreatic Adenocarcinoma

China
Jiangmen Central Hospital

Unknown

Toripalimab Combined With Gemcitabine/5--fluoropyrimidine for Advanced Cholangiocarcinoma

Advanced Cholangiocarcinoma

China
Fudan University

Recruiting

A Study of PD-1 Inhibitors Combined With Fruquintinib and Chemotherapy in First-line Treatment of HER2-negative Advanced G/GEJ Cancer (G/GEJ cancer)

Gastric Cancer/Adenocarcinoma of Esophagogastric Junction

China
Jiangsu Cancer Institute & Hospital

Active, not recruiting

Neoadjuvant Chemo-hypoRT Plus PD-1 Antibody (Tislelizumab) in Resectable LA-G/GEJ (RARE)

Gastric or Gastroesophageal Junction Adenocarcinoma

China
Peking University Cancer Hospital & Institute

Recruiting

Phase 2 Study of SBRT Plus Tislelizumab and Regorafenib in Unresectable or Oligometastatic HCC

Unresectable Hepatocellular Carcinoma | Oligometastatic Disease

China
Cancer Institute and Hospital, Chinese Academy...

Not yet recruiting

Nab-paclitaxel Combined With S-1 as Induction Therapy for Locally Advanced Pancreatic Cancer

Locally Advanced Pancreatic Cancer

China
Chongqing University Cancer Hospital

Completed

A Retrospective Analysis: Whether Five Factors Affect PFS in Patients With Locally Advanced Cervical Cancer

Radiotherapy | Locally Advanced Cervical Cancer

China
RenJi Hospital
Ruijin Hospital; Shanghai General Hospital, Shanghai Jiao Tong University School...

Unknown

An Open-label, Multicenter, Prospective Study of Irreversible Electroporation (Nano Knife) Combined With Radiotherapy and Chemotherapy in Patients With Locally Advanced Pancreatic Cancer

Pancreatic Cancer | Locally Advanced Pancreatic Caner

China
Peking Union Medical College Hospital

Not yet recruiting

Study of Anlotinib in Patients With Radioiodine Refractory Differentiated Thyroid Cancer

Locally Advanced or Metastatic Radioiodine-refractory Differentiated Thyroid Carcinoma

China
Changhai Hospital

Recruiting

Study of Immunotherapy Combined With Chemotherapy in Locally Advanced and Metastatic Pancreatic Cancer

Locally Advanced and Metastatic Pancreatic Cancer

China
Peking University Cancer Hospital & Institute

Enrolling by invitation

A Phase Ⅱ Trial of Neoadjuvant Toripalimab Plus Platinum-doublet Chemotherapy in Locally Advanced NSCLC.

Locally Advanced NSCLC

China
Sichuan Baili Pharmaceutical Co., Ltd.
SystImmune Inc.

Recruiting

A Study of SI-B001, an EGFR/HER3 Bispecific Antibody, in Locally Advanced or Metastatic Epithelial Tumors

Locally Advanced or Metastatic Epithelial Tumor

China
Chongqing University Cancer Hospital

Not yet recruiting

Study of Chemoradiotherapy With Envafolimab For The Treatment of Locally Advanced Cervical Cancer

Locally Advanced Cervical Cancer

China
Qilu Hospital of Shandong University

Not yet recruiting

Toripalimab Combined With Anlotinib in Unresectable Locally Advanced or Metastatic Acral Malignant Melanoma

Locally Advanced or Metastatic Acral Malignant Melanoma

China
Wen Li

Recruiting

HAIC+Lenvatinib+Tislelizumab vs D-TACE+Lenvatinib+Tislelizumab for Unresectable HCC

Unresectable Hepatocellular Carcinoma

China
First Affiliated Hospital Xi'an Jiaotong University
Nanjing Legend Biotech Co.

Terminated

A Phase 1 Study of LCAR-C182A Cells in the Treatment of Advanced Gastric Cancer and Pancreatic Ductal Adenocarcinoma

Gastric Cancer | Pancreatic Ductal Adenocarcinoma

China
Zhejiang Cancer Hospital

Recruiting

A Randomized, Multicenter Phase II Basket Study of Hypofractionated Radiotherapy/Stereotactic Body Radiotherapy Followed by Immunotherapy-Based Systemic Therapy +/- L. Rhamnosus M9 for the First-Line Treatment of Advanced Digestive System Malignancies.

Gastric Cancer | Colorectal Cancer | Pancreatic Adenocarcinoma | Biliary Tract Cancer | Gastroesophageal Junction Adenocarcinoma | Liver Cancer Stage IV

China
Hebei Medical University Fourth Hospital

Recruiting

Short-course Radiotherapy Followed by Tislelizumab + CapeOX in the Treatment for Locally Advanced Rectal Cancer

Locally Advanced Rectal Cancer

China
Fudan University

Recruiting

Cryoablation Combined With Sintilimab Plus Lenvatinib in 1L Treatment of Advanced ICC (CASTLE-ICC-Chemo-free)

Advanced Intrahepatic Cholangiocarcinoma

China
Hutchmed

Recruiting

Phase 2 Study of HMPL-453 Tartrate in Advanced Intrahepatic Cholangiocarcinoma

Advanced Intrahepatic Cholangiocarcinoma

China
MediLink Therapeutics (Suzhou) Co., Ltd.

Active, not recruiting

A Study of YL202 in Selected Patients With Advanced Solid Tumors

Breast Cancer | NSCLC | HNSCC | Locally Advanced or Metastatic Solid Tumors

China
Peking University
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Not yet recruiting

Anlotinib, TQB2450 (PD-L1 Inhibitor), and Albumin-bound Paclitaxel Regimens in the Treatment of GC/GEJA

Gastric Cancer | Adenocarcinoma of Esophagogastric Junction

China
The First Affiliated Hospital of Xiamen University

Recruiting

A Study of Paclitaxel Combined With Apatinib and Adebrelimab in Gastric/Gastroesophageal Junction Adenocarcinoma

Gastric/Gastroesophageal Junction Adenocarcinoma

China
Second Affiliated Hospital of Guangzhou Medical...
First Affiliated Hospital, Sun Yat-Sen University; First People's Hospital... and other collaborators

Recruiting

DEB-TACE+HAIC vs. HAIC for Large HCC

Unresectable Hepatocellular Carcinoma

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Active, not recruiting

Donafenib and Toripalimab Combined With TACE in Patients With Unresectable Hepatocellular Carcinoma

Unresectable Hepatocellular Carcinoma

China
Fudan University

Unknown

The Combination of Immunotherapy and Neoadjuvant Chemoradiotherapy in MSI-H Locally Advanced Rectal Cancer

Locally Advanced Rectal Cancer

China
Sun Yat-sen University

Not yet recruiting

Surufatinib and Serplulimab Combined With AG Regimen Compare With AG Regimen as Conversion Therapy for Patients With Locally Advanced Pancreatic Cancer (SAGE)

Locally Advanced Pancreatic Cancer

China
Eisai Co., Ltd.

Completed

Pharmacokinetic Study of E7080/Lenvatinib in Chinese Patients With Unresectable Hepatocellular Carcinoma (HCC)

Unresectable Hepatocellular Carcinoma (HCC)

China
AstraZeneca
Daiichi Sankyo Co., Ltd.

Completed

Study of T-DXd Monotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Gastric or GEJ Adenocarcinoma Who Have Received 2 or More Prior Regimens (DG-06)

Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

China
Tianjin Medical University Cancer Institute and...

Recruiting

HAIC Combined With Durvalumab, Tremelimumab and Bevacizumab as Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma

Unrescetable Hepatocellular Carcinoma

China
National Cancer Center Hospital East
Bayer Yakuhin, Ltd.

Active, not recruiting

Clinical Study of Regorafenib and Nivolumab Plus Chemotherapy

Gastric Adenocarcinoma | Esophageal Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

Japan
Wu Jun

Not yet recruiting

Efficacy and Safety of Sintilimab Combined With Nab-paclitaxel and Tegio (aTS) as First-line Treatment of Unresectable Locally Advanced, Recurrent or Metastatic Adenocarcinoma of Gastric and Gastroesophageal Junction，a Phase II Clinical Study

Adenocarcinoma | Gastric Cancer | GastroEsophageal Cancer

China
Zhejiang University

Recruiting

Serplulimab Combined With CAPEOX + Celecoxib as Neoadjuvant Treatment for Locally Advanced Rectal Cancer

MSS | Locally Advanced Rectal Carcinoma | pMMR | MSI-L

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Study on Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Patients With Advanced Biliary Adenocarcinoma/Hepatocellular Carcinoma

Advanced Biliary Adenocarcinoma/Hepatocellular Carcinoma

China
West China Hospital

Recruiting

FOLFOXIRI for Neoadjuvant Treatment of High-risk Locally Advanced Colorectal Cancer

Neoadjuvant Chemotherapy | High-risk Locally Advanced Colorectal Cancer | FOLFOXIRI Regimen

China
Sixth Affiliated Hospital, Sun Yat-sen University

Recruiting

Docetaxel, Oxaliplatin and 5-FU for Gastric Cancer With Inoperable Malignant Bowel Obstruction

Peritoneal Carcinomatosis | Metastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction Adenocarcinoma

China
National Cancer Center Hospital East
Daiichi Sankyo Co., Ltd.

Recruiting

Phase 2 Study of T-DXd in the Neoadjuvant Treatment for Patients With HER2 Positive Gastric and GEJ Adenocarcinoma

Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

Japan
Curegenix Inc.
Guangzhou Curegenix Co. Ltd.

Unknown

Phase 1 Dose Escalation Study of CGX1321 in Subjects With Advanced Gastrointestinal Tumors

Hepatocellular Carcinoma | Pancreatic Adenocarcinoma | Gastric Adenocarcinoma | Gastrointestinal Cancer | Esophageal Carcinoma | Colorectal Adenocarcinoma | Bile Duct Carcinoma

China
Guangdong Zhongsheng Pharmaceutical Co., Ltd.

Unknown

A Phase 1 Study of ZSP1241 in Participants With Advanced Solid Tumors

Hepatocellular Carcinoma | Gastric Cancer | Colorectal Cancer | Esophageal Cancer | Cholangiocarcinoma

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Terminated

A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Advanced Gastric Carcinoma

Advanced Gastric Carcinoma

China
Tianjin Medical University Cancer Institute and...

Recruiting

Camrelizumab Combined With Radiotherapy and Chemotherapy for the Treatment of Recurrent or Metastatic Cervical Cancer

Locally Advanced Cervical Cancer

China
Shanghai Zhongshan Hospital

Not yet recruiting

Synergistic Effects of PD-1 Antibody and Chemotherapy Followed by Surgery in Limited-metastatic G/GEJ Adenocarcinoma (ROSETTE)

Gastric Cancer | GastroEsophageal Cancer

China
RenJi Hospital
Beijing Viroad Biotechnology Co., Ltd.

Completed

CTC in Predicting Neoadjuvant Chemotherapy Among LABC Patients: a Single-center, Prospective, Exploratory Clinical Trial (CTCNeoBC)

Locally Advanced Breast Cancer | Circulating Tumor Cell

China
Yu jiren

Not yet recruiting

Perioperative Chemotherapy Plus Toripalimab for Epstein-Barr Virus-associated Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma

Adenocarcinoma of the Stomach | Adenocarcinoma of Esophagogastric Junction | Epstein-Barr Virus-Associated Gastric Carcinoma

China
InxMed (Shanghai) Co., Ltd.

Completed

IN10018 Monotherapy or in Combination With Docetaxel in Gastric or GEJ Adenocarcinoma

Gastric Cancer

China
West China Hospital

Recruiting

Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer

Locally Advanced Thyroid Gland Carcinoma

China
The Affiliated Nanjing Drum Tower Hospital of Nanjing...

Recruiting

Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer

Neoadjuvant Therapy | High Risk Prostate Cancer | Locally Advanced Prostate Cancer | Intense Endocrine Therapy

China

Clinical Trials on Locally Advanced Unresectable Gastric Adenocarcinoma in China

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Pakistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations